Hyperfine Swoop® System Referenced in France's Largest Public Hospital Procurement Body to Facilitate Nationwide Purchases of Portable MRI Technology

October 13, 2025

UniHA approves framework agreement covering over 1,500 French public hospitals, facilitating the purchase of Swoop® AI-powered portable MRI systems over three years

GUILFORD, Conn.--(BUSINESS WIRE)--Oct. 13, 2025-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that its distribution partner, UpCare Europe SAS (UpCare), has been awarded a national referencing for the Swoop® system by UniHA (Union des Hôpitaux pour les Achats), France's leading public healthcare purchasing cooperative.

UniHA provides a framework that facilitates centralized purchasing for more than 1,500 public hospitals and 130 regional hospital groups across France and French territories with the aim of accelerating the adoption of innovative healthcare technologies. This selection will enable hospitals to acquire Swoop® systems without initiating individual tenders, thus supporting streamlined procurement and removing barriers to adoption. The agreement, effective November 2, 2025, includes an allowance of Swoop® system purchases over the next three years, creating a pathway for broader deployment of portable brain imaging technology and marking the first time that portable brain MRI has been included in the UniHA framework.

"This award marks a major milestone in the evolution of patient care," said Benoit Sai, Co-founder and Chief Commercial Officer of UpCare. "We are proud to partner with Hyperfine to help broaden adoption of the Swoop® system throughout France. Ultra-low-field MRI is not merely a technological innovation—it is a transformative response to today's medical, logistical, and socio-economic challenges. I deeply commend UniHA, Hyperfine, and the French hospital community for their foresight and leadership in advancing imaging access and quality."

"Being referenced by UniHA is an important recognition of the value of our technology and builds on the momentum we are getting in European markets, following the recent CE marking of our Optive AI™ software," saidMaria Sainz, President and CEO of Hyperfine, Inc. "France represents one of Europe's most strategic healthcare markets, and we are proud to partner with UpCare to support French hospitals with advanced imaging solutions that bring care closer to patients."

For more information about the Swoop® system, please visit HyperfineMRI.com.

About the Swoop® Portable MRI Systems

The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the *Swoop*® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those

markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013563494/en/

Media Contact
Devin Zell
Hyperfine
dzell@hyperfine.io

Investor Contact
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com

Source: Hyperfine, Inc.